Modafinil vs armodafinil

This page is a reference summary of published evidence and regulatory documents. It is not a substitute for individual medical advice, and it is not a recommendation to take or avoid any medicine.

Medically reviewed by Dr. Sofia Lindqvist, · Last reviewed 11 August 2026

Modafinil and armodafinil are the same molecule at different levels of purification: modafinil is a 50:50 racemic mixture of two enantiomers, and armodafinil is the R-enantiomer alone. They have similar elimination half-lives, roughly 13-15 hours for both, and neither is clearly longer- or shorter-acting than the other in a way supported by a comparative trial.

The commonly repeated claim that armodafinil “lasts longer” is imprecise. What differs is the shape of the plasma concentration curve, not the duration of drug in the body.

Comparison table

Modafinil Armodafinil
Composition Racemic mixture (R- and S-modafinil) R-enantiomer only
Typical dose 200mg once daily 150mg once daily (up to 250mg in shift work disorder)
Elimination half-life ~15 hours (racemate, dominated by R-isomer) ~13-15 hours
Approved indications Narcolepsy, OSA-associated sleepiness, shift work disorder Same three indications
FDA approval year 1998 2007
Manufacturer of brand product Cephalon (Provigil) Cephalon/Teva (Nuvigil)

Half-life figures from FDA-approved prescribing information; both are approximate population means with wide inter-individual variation.

Mechanism difference

Both drugs act primarily through dopamine transporter (DAT) inhibition, raising synaptic dopamine and producing downstream effects on histaminergic, orexinergic, and noradrenergic wake-promoting systems. The R-enantiomer in armodafinil is cleared more slowly than the S-enantiomer that is also present in modafinil, so isolating the R-form changes the plasma profile without introducing a new mechanism.

Where they differ

The clearest documented difference is the concentration-time curve. Because armodafinil delivers only the slower-cleared R-enantiomer, plasma concentrations later in the day are higher relative to the initial dose than with an equivalent dose of racemic modafinil, whose S-isomer is cleared faster and contributes disproportionately to the early peak. This is a difference in curve shape, not in total duration of action, and it has not been shown to translate into a clinically meaningful difference in wakefulness at a given clock time.

 

Dose equivalence is approximate rather than exact: 150mg armodafinil is generally treated as roughly comparable to 200mg modafinil, based on the proportion of active R-isomer in a standard modafinil dose, not on a dedicated bioequivalence trial between the two products.

Where they are the same

No randomized head-to-head trial has compared modafinil and armodafinil directly on a clinical wakefulness outcome. Claims that one outperforms the other rest on separate placebo-controlled trials and pharmacokinetic inference, not on a comparative study.

Approved indications are identical: narcolepsy, obstructive sleep apnea with residual excessive sleepiness despite treatment of the underlying disorder, and shift work disorder. Both carry the same boxed warning history around serious skin reactions (Stevens-Johnson syndrome and related conditions), the same CYP3A4 induction that reduces hormonal contraceptive efficacy, and comparable common side-effect profiles: headache, nausea, and insomnia are the most frequently reported for both. Both are Schedule IV controlled substances in the United States with a similarly low reported abuse potential in clinical trial populations.

Who each tends to suit

In practice the choice is often driven by formulary availability, insurance coverage, or a prescriber’s prior experience rather than a pharmacological reason to prefer one. Some patients report that armodafinil’s flatter, more sustained late-day concentration suits afternoon alertness better; others find no subjective difference. Neither preference has been validated in a controlled comparison, so a trial of either, under medical supervision, is the practical way to determine individual response.

Frequently asked questions

Does armodafinil really last longer than modafinil?

No. Both have elimination half-lives in the same range, roughly 13-15 hours. Armodafinil produces a higher plasma concentration later in the day because it is a single enantiomer that is not diluted by the faster-cleared S-isomer present in modafinil, which changes the shape of the curve, not its duration.

Is armodafinil just double-strength modafinil?

No. A 150mg armodafinil dose is roughly comparable to 200mg modafinil in effect, not to 300mg, because modafinil is a racemate and only its R-enantiomer is armodafinil.

Is there a trial showing armodafinil works better?

No head-to-head trial has been conducted comparing the two drugs directly on a clinical outcome. Claims of superiority rest on pharmacokinetic reasoning and separate placebo-controlled trials, not on a comparative trial.

Can I switch between them freely?

Only under medical guidance. Because approved doses and formulations differ, and because both share the same rare serious skin-reaction warning, a clinician should manage any switch.

References